Pancreatic Carcinoma
3 drugs11,007 FAERS reportsMedDRA PT
GET
/api/v1/reaction/pancreatic-carcinomaReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D010190
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Source: U.S. National Library of Medicine — MeSH (Pancreatic Neoplasms)
Drugs reporting Pancreatic Carcinoma (3)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Ranitidine8,0373.5%
- 2Sitagliptin2,0072.2%
- 3Liraglutide9631.9%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Pancreatic Neoplasms as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Trends in Pancreatic Cancer Incidence, Mortality and Net Survival: A Population-Based Analysis in Zurich (Switzerland), 1981-2021.Journal of gastrointestinal cancer · 2026 · Vinci L, Wanner M, Wicki A, et al.PMID 42207346DOI 10.1007/s12029-026-01498-8
- Evaluation of the efficacy of plan adaptation in stereotactic body proton therapy for pancreatic cancer.Journal of applied clinical medical physics · 2026 · Matsuo Y, Uchinami Y, Katoh N, et al.PMID 42206597DOI 10.1002/acm2.70644
- LINC00852 Enhances Glycolysis and Tumor Immunity in Pancreatic Cancer via the miR‑494‑3p/GPX8 Axis.Journal of biochemical and molecular toxicology · 2026 · Wang C, Li Y, Tian B, et al.PMID 42204968DOI 10.1002/jbt.70871
- NF-κB inducing kinase (NIK) deletion accelerates KRAS-driven pancreatic cancer in association with tumor microenvironment remodeling.Cell death & disease · 2026 · Du Z, Büttner UFG, Wirth HL, et al.PMID 42203767DOI 10.1038/s41419-026-08877-w
- Preoperative Serum Total Cholesterol Predicts Adjuvant Chemotherapy Completion After Pancreaticoduodenectomy for Pancreatic Cancer.Anticancer research · 2026 · Hatta K, Nishimura S, Tanaka R, et al.PMID 42203346DOI 10.21873/anticanres.18203
- Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan-Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer.Anticancer research · 2026 · Maeda K, Koyama S, Kawada K, et al.PMID 42203343DOI 10.21873/anticanres.18190
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.